148 related articles for article (PubMed ID: 6354509)
1. Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA).
Shipp SK; Muss HB; Westrick MA; Cooper MR; Jackson DV; Richards FC; White DR; Stuart JJ; Christian RM; Ramseur W
Cancer Chemother Pharmacol; 1983; 11(2):130-3. PubMed ID: 6354509
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
3. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
Colozza M; Tonato M; Grignani F; Davis S
Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
[TBL] [Abstract][Full Text] [Related]
4. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
5. [A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Tada A; Ueno K; Yamazaki H; Nakamura T; Ito Y; Inagaki J
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):327-32. PubMed ID: 2494947
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
8. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
9. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
[TBL] [Abstract][Full Text] [Related]
12. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
13. The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
Kojima T; Hoshino A; Ohara K; Kamiya O; Nagata K; Ito Y; Kinoshita T; Sugiura I; Yamada M; Sato H
Cancer Chemother Pharmacol; 1985; 15(3):268-71. PubMed ID: 3902267
[TBL] [Abstract][Full Text] [Related]
14. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association.
Muss HB; Richards F; Jackson DV; Cooper MR; White DR; Stuart JJ; Ramseur W; Christian RM; Wells HB; Pope E; Spurr CL
Cancer; 1982 Dec; 50(11):2269-74. PubMed ID: 6754062
[TBL] [Abstract][Full Text] [Related]
15. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy induces regression of brain metastases in breast carcinoma.
Rosner D; Nemoto T; Lane WW
Cancer; 1986 Aug; 58(4):832-9. PubMed ID: 3755076
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast. A phase III study of the Piedmont Oncology Association (POA).
Zekan PJ; Muss HB; Capizzi RL; Cooper MR; Harding RW; Hopkins JO; Jackson DV; Ramseur WL; Richards F; Spurr CL
Cancer; 1984 Dec; 54(11):2338-43. PubMed ID: 6388802
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
Pronzato P; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso R
Anticancer Res; 1990; 10(6):1743-5. PubMed ID: 2126683
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM): an effective program for breast cancer, even for disease refractory to previous chemotherapy. A Northern California Oncology Group (NCOG) Study.
Friedman MA; Marcus FS; Cassidy MJ; Resser KJ; Kohler M; Hendrickson CG; Reynolds R; Johnson D; Kilbridge T; Yu K; Cruicitt M
Cancer; 1983 Jul; 52(2):193-7. PubMed ID: 6344976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
